Bio-Techne Corp (TECH)

Current ratio

Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020
Total current assets US$ in thousands 608,300 627,240 634,640 648,567 617,419 610,650 590,640 591,477 621,482 570,996 565,183 552,031 605,556 593,108 590,230 543,748 510,606 566,606 541,933 541,893
Total current liabilities US$ in thousands 175,849 169,204 161,256 142,128 159,379 149,820 135,231 127,754 128,509 141,163 128,395 137,629 176,018 166,838 154,809 133,992 152,284 137,640 117,568 105,424
Current ratio 3.46 3.71 3.94 4.56 3.87 4.08 4.37 4.63 4.84 4.04 4.40 4.01 3.44 3.55 3.81 4.06 3.35 4.12 4.61 5.14

June 30, 2025 calculation

Current ratio = Total current assets ÷ Total current liabilities
= $608,300K ÷ $175,849K
= 3.46

The analysis of Bio-Techne Corp’s current ratio over the specified period reveals a generally stable liquidity position, with ratios predominantly maintained above 3.0 and frequently exceeding 4.0. At the end of September 2020, the current ratio was notably high at 5.14, indicating a strong liquidity buffer relative to current liabilities. Throughout 2020 and into the first quarter of 2021, the ratio experienced a gradual decline, reaching 4.12 by March 31, 2021, and further decreasing to 3.35 by June 30, 2021. This downward trend persisted into late 2021, with the ratio oscillating between approximately 3.81 and 4.06, reflecting ongoing adjustments but maintaining a comfortable liquidity margin.

Beginning in 2022, the current ratio continued to hover within the 3.4 to 4.4 range, with minor fluctuations. Notably, the ratio increased to 4.84 at the end of June 2023, suggesting a momentary strengthening in short-term liquidity. Subsequently, it slightly declined to 4.63 in September 2023, before decreasing again to 4.37 at the close of December 2023. Moving into 2024, the ratio experienced minor fluctuations, with 4.08 in March, dipping to 3.87 in June, then rising to 4.56 in September, and declining again to 3.94 in December 2024.

Projections into 2025 show continued stability, with the ratio gradually decreasing from 3.71 in March to 3.46 by June 2025. These trends suggest that Bio-Techne maintains a robust liquidity position over the period, with current ratios well above the generally accepted threshold of 1.0, indicating the company’s ability to meet short-term obligations comfortably. The fluctuations observed are within a narrow range and reflect operational and strategic adjustments rather than significant liquidity concerns.